On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
Meta is testing a new type of non-skippable ad in the Instagram feed, which the company is calling an “ad break.”
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|